![The World Congress on Controversies in Obstetrics, Gynecology and Infertility (COGI). Click here to learn more.]({"type":"image" , "src" : "/sda/112382/JournalAd-COGI2024-Leaderboard.jpg"})
Reference
- Goetzl L, Shipp TD, Cohen A, Zelop CM, Repke JT, Lieberman E. 2001. Oxytocin dose and the risk of uterine rupture in a trial of labour after caesarean. Obstetrics and Gynaecology: 381 — 384.
- Kelly AJ, Kavanagh J, Thomas J. 2003. Vaginal prostaglandin (PGE2 and PGF2a) for induction of labour at term. Cochrane Database Systematic Review, 4, CD003101.
- Kunm A, Arulkumaran S, Tay D, Ingemarsson I, Ramam SS. 1991. Can terbutaline be used as a nebuliser instead of intravenous injection for inhibition of uterine activity? Gyneco-logic and Obstetric Investigation 32:84— 87.
- Royal College of Obstetricians and Gynaecologists. 2001. Induc-tion of labour. Evidence-based Clinical Guideline No 9. London: RCOG Press.
- Shetty A, Livingstone I, Acharya S, Rice P, Danielian P, Templeton A. 2004. A randomised comparison of oral misoprostol and vaginal prostaglandin E2 tablets in labour induction at term. British Journal of Obstetrics and Gynaecology 111:436— 40.
- Shyken JM, Petrie RH. 1995. The use of oxytocin. Clinical Perinatology 22:907 — 931.
- Steer PJ. 2002. Cephalopelvic disproportion and abnormal uterine action. In: Chamberlain G, Steer P, editors. Turnbull's obstetrics, 3rd ed. London. Churchill Livingstone. Ch. 33, pp 533 — 544.